News - afatinib, Markets & Marketing

Filter

Popular Filters

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Analysts view Boehringer Ingelheim's first move into cancer drug market

11-10-2012

German family-owned drug major Boehringer Ingelheim last month announced the submission of a Marketing…

afatinibBoehringer IngelheimMarkets & MarketingnintedanibOncologyPharmaceuticalResearchvolasertib

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

Back to top